RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
NCT06404112 is a phase 2 interventional trial sponsored by Duke University. As of 21 Nov 2026, it is completed. It studies Melantonin Placebo and Melatonin in Long COVID, Long COVID-19 and 1 more condition. The registry lists an enrollment of 469 participants at 1 site in 1 country. The registry lists a start date of 31 Jul 2024 and a primary completion date of 26 Feb 2026.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06404112 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Duke University |
| Enrollment | 469 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Long COVID, Long COVID-19 and Sleep Disturbance |
| Drugs | Melantonin Placebo and Melatonin |
| Start | 31 Jul 2024 |
| Primary completion | 26 Feb 2026 |
| Study completion | 1 Apr 2026 |
| Last update posted | 8 Jul 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Christina Barkauskas, MD
Duke Clinical Research Institute
Study Chair - Susan Redline, MD MPH
Brigham and Women's Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- All Sites Listed Under Nct06404086
Durham
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06404112
Each answer restates registry values shown on this page.
What is NCT06404112?
NCT06404112 is a phase 2 interventional trial sponsored by Duke University. It studies Melantonin Placebo and Melatonin in Long COVID, Long COVID-19 and 1 more condition.
Who leads NCT06404112?
The registry names Christina Barkauskas, MD (study chair, Duke Clinical Research Institute) and Susan Redline, MD MPH (study chair, Brigham and Women's Hospital) as overall officials.
Where does NCT06404112 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06404112 study?
The registered drug and biological interventions are Melantonin Placebo and Melatonin.
When did NCT06404112 end?
The registry lists a primary completion date of 26 Feb 2026 and a study completion date of 1 Apr 2026. The sponsor last updated the record on 8 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.